Compare Johnson & Johnson (JNJ) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Otis Worldwide Corp — how do they compare? Johnson & Johnson trades at $250.38 (market cap $598.96B), while Otis Worldwide Corp trades at $72.38 (market cap $28.20B). The key difference: Johnson & Johnson is far larger — about 21.2× Otis Worldwide Corp's market cap, and Otis Worldwide Corp pays the higher dividend (2.31%). Which is the better fit depends on your goals.
| JNJ | OTIS | |
|---|---|---|
Market Cap | $598.96B | $28.20B |
Volume | 6,156,228 | — |
Sector | Health | Industrials |
52-Week High | $267.24 | $100.99 |
52-Week Low | $164.36 | $69.34 |
Enterprise Value | $631.90B | $35.58B |
Dividend Yield | 2.15% | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Otis Worldwide trades at $73.49, showing minimal daily movement with a slight 0.05% gain. The stock maintains a bullish technical signal, supported by moving averages, while oscillators remain neutral. Recent earnings have been mixed, with Q1 2026 missing estimates despite service growth. The company continues strategic initiatives, including dividend increases and modernization projects, as highlighted in recent corporate announcements.
Outlook remains cautiously optimistic with a consensus price target of $91, offering significant upside. Risks include margin pressures from tariffs and regional delays, but strong service revenue growth and a reasonable valuation provide a foundation for recovery. Investors should weigh near-term headwinds against long-term operational strengths.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
